Key result
Medical treatment for primary aldosteronism predicts ~388% higher odds of persistent LVH compared to surgery.
Why the study?
Persistent cardiac organ damage had not been compared between patients treated surgically versus medically for primary aldosteronism.
Does surgical treatment compared to medical treatment improve persistent cardiac organ damage in patients with primary aldosteronism?
Cohort (n=84)
Does surgical treatment compared to medical treatment improve persistent cardiac organ damage in patients with primary aldosteronism?
Surgical treatment of primary aldosteronism leads to better regression of left ventricular hypertrophy at one year compared to medical treatment.
Answers are grounded in this paper and cite their sources.
Medical treatment was associated with persistent LV hypertrophy; hypothesis-generating for surgical preference, pending randomized trials.
OBJECTIVE: We compared persistent cardiac organ damage in patients treated surgically or medically for primary aldosteronism. METHODS: Eighty-four patients (age 57 ± 11 years, 27% women) with primary aldosteronism underwent echocardiography at time of diagnosis and after one year of treatment (49% adrenalectomy, 51% medical treatment). Persistent cardiac organ damage was defined as presence of left ventricle (LV) hypertrophy, low LV midwall shortening, global longitudinal strain and/or enlarged left atrium both at baseline and at follow-up. RESULTS: At one year, a significant regression of LV hypertrophy was observed in surgically (44 vs. 22%, P = 0.039), but not in medically treated patients (60 vs. 51%, P = 0.206). The prevalence of enlarged left atrium was reduced in both groups (both P < 0.001), whereas systolic myocardial function remained unchanged. In multivariable logistic regression analysis, medical treatment [odds ratio (OR) 4.88 (95% confidence interval (CI) 1.26-18.88)] was a strong predictor of persistent LV hypertrophy independent of higher BMI [OR 1.20 (95% CI 1.04-1.38)] and presence of diabetes [OR 6.48 (95% CI 1.20-34.83), all P < 0.05]. Persistently low midwall shortening was associated with suppressed plasma renin after one year [OR 6.11 (95% CI 1.39-26.7)] and lower renal function [OR 0.96 (95% CI 0.94-0.99), both P < 0.05]. The strongest predictor of persistently low global longitudinal strain was higher HbA1c [OR 2.37 (95% CI 1.12-5.02), P = 0.024]. CONCLUSION: Persistent cardiac organ damage was more common in the medical treatment group and associated with incomplete aldosterone blockade, impaired renal function and presence of metabolic comorbidities. http://links.lww.com/HJH/B925.
No takes yet. Share an insight, caveat, or question.
Aune et al. (2022) conducted a cohort in Primary aldosteronism (n=84). Medical treatment vs. Surgical treatment (adrenalectomy) was evaluated on Persistent left ventricular hypertrophy (OR 4.88, 95% CI 1.26-18.88, p=< 0.05). Medical treatment for primary aldosteronism was a strong predictor of persistent left ventricular hypertrophy at one year compared to surgical treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: